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Dr. Ruperto and colleagues are quite right to defend
the combined use of infliximab and methotrexate in children
with JRA. Indeed, while their study failed to demonstrate
statistically significant efficacy at the primary end point, it is
widely agreed that the combination works. I doubt that any
rheumatologists treating children will change their practice
based on the results of this study, and that of course is my
point.
Their argument that D-penicillamine and auranofin
proved inefficacious in JRA holds little merit, since despite the
early industry-supported studies suggesting efficacy in adults
and children (including those conducted by some of the
authors of the study by Ruperto et al) (1,2), these compounds
were recognized to be ineffective in adults before the trial
showing lack of efficacy in children (3–5).
Despite the improvement represented by recent US
FDA and EU regulations requiring trials of new agents in
children (6,7), industry-sponsored investigation must always be
interpreted cautiously. The study design in which only those
children who respond to an agent are entered into the ran-
domized trial to determine if they experience a disease flare
when the agent is replaced by placebo may be ethically
necessary, but it is fundamentally flawed.
There are limited patient and personnel resources in
pediatric rheumatology. As argued by Morgan DeWitt et al, in
a perfect world all medications would be fully studied in each
of the subgroups of the several distinct diseases grouped under
the heading of juvenile idiopathic arthritis, each of which
probably has a distinct natural history and pathogenesis.
However, we clearly lack the patient numbers and resources to
accomplish this. When investigators, patients, and allied health
personnel devote their time to participating in a study, their
time is equally occupied whether the study is a clinical trial
conducted for registration purposes by a pharmaceutical com-
pany or an independent investigator-initiated trial. The phar-
maceutical company–initiated trials in pediatric rheumatology
have added little to our understanding of the basic science of
these diseases. Scientific understanding which will promote a
better future for children with rheumatic diseases is where the
excellent resources of PRINTO, CARRA, and PRCSG and
the limited resources of pediatric rheumatologists should be
dedicated.
Thomas J. A. Lehman, MD
Hospital for Special Surgery
and Weill Medical Center of Cornell University
New York, New York
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MEK/ERK pathway inhibitors as a treatment for
inflammatory arthritis might result in the
development of lupus: comment on the article by Thiel
et al
To the Editor:
We read with interest the article by Thiel et al describ-
ing the role of the MEK/ERK pathway in murine collagen-
induced arthritis (1). We are concerned with the idea of using
MEK/ERK inhibition as a potential treatment for rheumatoid
arthritis and other inflammatory diseases, as the authors
suggest. The authors did not cite any of the work that clearly
indicates a role for reduced MEK/ERK signaling in T cells in
the pathogenesis of lupus.
MEK/ERK pathway signaling regulates, at least in
part, the expression of the chief “maintenance” DNA methyl-
ation enzyme, Dnmt1 (2). T cells from lupus patients have
defective MEK/ERK pathway signaling, which results in re-
duced Dnmt1 expression and global T cell DNA hypomethyl-
ation (3). As a result, a number of methylation-sensitive genes,
such as TNFSF7 (CD70), ITGAL (CD11a), PERF (perforin),
and CD40LG (CD40L), are overexpressed in lupus T cells
(4,5). The MEK/ERK signaling defect in lupus T cells is
proportional to disease activity (3). Moreover, treating T cells
with MEK/ERK pathway inhibitors results in reduced Dnmt1
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expression, and overexpression of the same methylation-
sensitive genes similar to T cells from lupus patients (6,7).
CD4 T cells treated with MEK/ERK pathway inhibitors
become autoreactive in vitro, as demonstrated by their ability
to respond to syngeneic antigen-presenting cells without anti-
gen and their ability to induce immunoglobulin production in
coculture with autologous B cells (6,7). In addition, T cells
treated with selective MEK/ERK inhibitors induced anti–
double-stranded DNA antibody production when injected into
syngeneic mice similar to T cells treated with DNA methyl-
ation inhibitors (6,8). The lupus-inducing drug hydralazine is a
MEK/ERK pathway inhibitor (6). T cells treated with hydral-
azine showed reduced DNA methylation, were autoreactive in
vitro, and were capable of inducing autoimmunity in vivo upon
adoptive transfer into mice (6,9). Therefore, the data demon-
strate a pathogenic role for defective MEK/ERK pathway
signaling in lupus. We would caution that using MEK/ERK
pathway inhibitors as a treatment in patients with inflamma-
tory arthritis might result in the development of a lupus-like
disease.
Amr H. Sawalha, MD
University of Oklahoma Health Sciences Center
US Department of Veterans Affairs Medical Center
Oklahoma Medical Research Foundation
Oklahoma City, OK
Bruce Richardson, MD, PhD
University of Michigan
US Department of Veterans Affairs Medical Center
Ann Arbor, MI
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We thank Drs. Sawalha and Richardson for their
comments. I would like to emphasize that the main purpose of
this article, using the MEK inhibitor as a tool, was to delineate
the role of the MEK/ERK pathway in this mouse model of
rheumatoid arthritis (RA), and to argue that MEK is as
integral to inflammatory processes as are the JNK and p38
MAP kinase pathways. The potential safety implications for
clinical use, including the concerns by the authors of the letter,
certainly would be explored in depth if this were to be pursued
as a potential therapeutic approach for human RA. We did,
however, investigate the effects of MEK inhibition on CD11a
expression in our animal models following prolonged dosing
with the MEK inhibitor.
While certainly not an exhaustive evaluation of the
potential issues noted by Drs. Sawalha and Richardson, we
found no evidence of CD11a up-regulation on splenocyte
CD4, CD8, or B cell subpopulations. We were also sur-
prised, to be honest, and as noted in the article, that animals
treated for long periods of time with the MEK inhibitors were
not globally immunosuppressed; in fact, we could not show
that they were immunocompromised in any way. This was
surprising and encouraging in light of the significant literature
demonstrating the suppressive effects of MEK inhibition on a
variety of leukocyte types in vitro, but, more importantly,
illustrates that in vitro phenomena do not always translate to
the whole organism.




Identity of single-nucleotide polymorphisms used in a
clinical pharmacogenetic model to predict the efficacy
of methotrexate monotherapy: comment on the article
by Wessels et al
To the Editor:
We were very interested to read the article by Wessels
et al (1), which describes a clinical pharmacogenetic model
that may predict response to methotrexate therapy in patients
with recent-onset rheumatoid arthritis. The model incorpo-
rates sex, rheumatoid factor status, smoking status, Disease
Activity Score, and 4 polymorphisms in the adenosine mono-
phosphate deaminase (AMPD1), aminoimidazole carboxamide
ribonucleotide transformylase (ATIC), inosine triphosphate
pyrophosphatase (ITPA), and methylenetetrahydrofolate de-
hydrogenase (MTHFD1) genes. We agree that this approach of
using a “pharmacogenetic index” based upon a cumulative
effect of multiple polymorphisms and clinical factors may
prove to be the best predictive model for a number of drugs,
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